title: Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.
authors.affiliation: National Cancer Institute, Division of Cancer Treatment and Diagnosis, Biomedical Imaging Program, Bethesda, Maryland 20892, USA. kelloffg@mail.nih.gov
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Kelloff
authors.forename: Joyce A
authors.initials: JA
authors.lastname: O'Shaughnessy
authors.forename: Gary B
authors.initials: GB
authors.lastname: Gordon
authors.forename: Ernest T
authors.initials: ET
authors.lastname: Hawk
authors.forename: Caroline C
authors.initials: CC
authors.lastname: Sigman
mesh_terms: D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D017322:Clinical Trials, Phase II as Topic; D017277:Drug Approval; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000473:pathology / Q000517:prevention & control*; D009385:Neoplastic Processes; D010641:Phenotype; D011230:Precancerous Conditions / Q000517:prevention & control*; D011237:Predictive Value of Tests; D015203:Reproducibility of Results
chemical_list: D016588:Anticarcinogenic Agents; D014408:Biomarkers, Tumor